| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Beta Bionics, Inc.$17.03
+0.6 (+3.65%)
C 59Pipeline Score MedTech · Commercial
Market Cap
526.72 M
EPS
-1.51
P/E Ratio
-
Value Trade
13.18 M
SEC Financials
Q1 2026Dilution Risk
Revenue
27.63 M
R&D Expenses
10.36 M
Operating CF
-23.83 M
Total Assets
304.42 M
Total Liabilities
33.17 M
Equity
271.25 M
D/E Ratio
12,345
30.9 %
Week
-8.8 %
1 Month
-13.72 %
3 Month
-58.13 %
6 Month
-46.27 %
5 Year
-46.27 %
All Time
Cash Data
Cash Position
199.52 M
Monthly Burn
7.94 M
Runway
22.4 mo
Burn Trend
SEC Filing
Apr 21, 2026
Overview
Volume
1.06 M
52 Week Range
8.80 - 32.71
% held by Insiders
25.17 %
% held by Institutions
97.99 %
Enterprise Value
334.01 M
Total Shares
44.41 M
Short %
18.11 %
Float Shares
37.66 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Beta Bionics, Inc.
1Total events
1Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Upcoming catalysts 1
Drug Pipeline Intelligence
C59
Pipeline Score $3.6B
Pipeline ValueValuation Signal
2
Drugs Scored6.9x
rNPV / MCap Top 86%
Micro Cap (rank 129 of 912)
Percentile RankBeta Bionics, Inc. carries a moderate pipeline score (59/100), with $13.8B risk-adjusted pipeline value, led by Dasiglucagon in Type 1 Diabetes Mellitus (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dasiglucagon Small molecule | Type 1 Diabetes Mellitus | Phase 2 | NCT03840278 | 43% | $9.1B | COMPLETED | 12 | - | - | Jul 3, 2019 | - | Dec 16, 2019 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
iLet® Bionic Pancreas | type 1 diabetes | — | 2021-12-22 | approximately 440 adults and children 6 years and older with type 1 diabetes Read More | Beta Bionics Announces Data Lock of the Insulin-Only Bionic Pancreas Pivotal Trial and Enrollment into the Screening Protocol of the Bihormonal Bionic Pancreas Pivotal Trial Read More | |
iLet® Bionic Pancreas | type 1 diabetes | — | 2021-12-22 | approximately 440 adults and children 6 years and older with type 1 diabetes Read More | Beta Bionics Announces Data Lock of the Insulin-Only Bionic Pancreas Pivotal Trial and Enrollment into the Screening Protocol of the Bihormonal Bionic Pancreas Pivotal Trial Read More | |
iLet® Bionic Pancreas | type 1 diabetes | — | 2021-12-22 | approximately 440 adults and children 6 years and older with type 1 diabetes Read More | Beta Bionics Announces Data Lock of the Insulin-Only Bionic Pancreas Pivotal Trial and Enrollment into the Screening Protocol of the Bihormonal Bionic Pancreas Pivotal Trial Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BBNX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BBNX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BBNX▲ +6.6%on this news
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
Beta Bionics, Inc. announced it will release its second quarter 2026 financial results on July 29, 2026. A conference call and webcast will follow the release to discuss the company's performance. The iLet Bionic Pancreas, an FDA-cleared device, aims to enhance diabetes management for insulin-requiring individuals.
Read more →BBNX▼ -5.4%on this news
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Johnson Fistel, PLLP is investigating potential securities law violations involving Beta Bionics, Inc. The investigation is driven by concerns that the company or its executives may have made false statements regarding growth trends and patient starts, particularly following the announcement of a significant slowdown in new patient starts during Q4 2025. The results, while showing some growth, were still below analyst expectations and indicated a notable deceleration compared to the previous quarter. Investors who suffered losses are encouraged to participate in the investigation for possible legal recourse.
Read more →BBNX▲ +7.1%on this news
Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth
Johnson Fistel is conducting an investigation into possible securities law violations for Beta Bionics following concerns raised by slower new patient start growth. The investigation was prompted by the company's recent disclosure that indicated disappointing growth metrics for the fourth quarter of 2025. Despite reporting some year-over-year growth, the figures fell short of analyst expectations and showed a marked decline from prior performance. Investors who have suffered losses in Beta Bionics securities are invited to participate in the investigation.
Read more →BBNX▲ +11.6%on this newsshared move
Beta Bionics, Inc. (BBNX) Investigation: Johnson Fistel Investigates Investor Losses Following Slower New Patient Start Growth
Johnson Fistel is investigating Beta Bionics, Inc. following disappointing financial results for the fourth quarter of 2025, where new patient starts growth slowed considerably to 36%, down from 68% in the previous quarter. The stock price dropped over 35% after this news, prompting concerns about compliance with federal securities laws. Investors who have suffered losses may join the investigation regarding the company's disclosures and executive conduct.
Read more →BBNXBeta Bionics, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in BBNX Due to Possible Violations of Securities Laws
Robbins LLP is investigating Beta Bionics, Inc. for possible securities law violations related to management's actions and fiduciary duties toward shareholders. The investigation follows the company's announcement of preliminary unaudited results for Q4 2025, which showed lower-than-expected growth in new patient starts, leading to a significant drop in stock price. Investors who suffered losses are encouraged to contact Robbins LLP for legal assistance.
Read more →BBNXBeta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website
Beta Bionics has launched a public dashboard providing near real-time real-world data on its iLet Bionic Pancreas. This innovative approach allows healthcare providers and the diabetes community to access comprehensive outcomes without exclusions. The initiative aims to enhance transparency in automated insulin delivery and sets a new standard for data evaluation in the industry.
Read more →BBNX▲ +5.6%on this newsshared move
Beta Bionics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses
Johnson Fistel, PLLP is conducting an investigation into Beta Bionics, Inc. concerning potential violations of federal securities laws related to reported investor losses. This follows the company's recent disclosure, which revealed a lower-than-expected growth in new patient starts and resulted in a significant drop in stock price. Investors concerned about their losses are encouraged to contact Johnson Fistel for more information on the investigation and recovery possibilities.
Read more →BBNX▲ +11.4%on this news
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development
Beta Bionics has updated its timeline for the commercialization of Mint, an advanced insulin pump, expecting to launch by the end of Q2 2027, pending FDA approval. The company is confident in its manufacturing capabilities to meet demand and believes Mint will significantly enhance diabetes management options for users. Further details will be provided once regulatory clearance is obtained.
Read more →BBNXBeta Bionics to Present at the Bank of America Securities Health Care Conference
Beta Bionics, Inc. will present at the Bank of America Securities Health Care Conference on May 12, 2026. The company focuses on advanced diabetes management solutions and is known for its iLet Bionic Pancreas, the first FDA-cleared insulin delivery device. A live audio webcast of the presentation will be accessible on their investor website, providing insights into the company's developments and offerings.
Read more →BBNXBeta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
Beta Bionics, Inc. reported its financial results for Q1 2026, showing a 57% increase in net sales compared to the same quarter last year, reaching $27.6 million. Despite a decline in new patient starts and a loss from operations of $24.3 million, the company raised its full-year guidance for total revenue. The gross margin exhibited significant improvement, rising to 59.5%. Additionally, recent strategic actions include the launch of a new data analytics feature and the initiation of a Phase 2a trial in New Zealand for their bihormonal system.
Read more →BBNX▲ +11.1%on this news· ran to +22% by day 1
Beta Bionics, Inc. Investigated by the Portnoy Law Firm
Beta Bionics, Inc. is under investigation by the Portnoy Law Firm for possible securities fraud, potentially leading to a class action lawsuit for investors. This development comes after a significant drop in the company's stock price, which fell 37.03% following an earnings report indicating a drastic slowdown in new user acquisitions. The report showed a stark contrast in growth from the previous quarter, leading to diminished investor confidence and increased concerns about the company's future performance. The law firm is offering complimentary evaluations to affected investors, highlighting the potential for pursuing claims due to corporate mismanagement.
Read more →BBNXBeta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care
Beta Bionics has launched Bionic Insights, a feature within its Bionic Reports that aims to enhance how healthcare providers make treatment decisions for diabetes patients. This innovative tool provides detailed insights into patient data by categorizing it into areas of success and opportunity, allowing clinicians to focus on actionable outcomes. The development is expected to improve patient care and glucose control by enabling more informed, personalized recommendations. Beta Bionics continues its commitment to simplifying diabetes management through advanced technology.
Read more →BBNX▼ -8.4%on this newsshared move
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
Beta Bionics, Inc. will announce its first quarter 2026 financial results on April 21, 2026. The announcement will be followed by a conference call and webcast at 4:30 PM ET to discuss the company's performance. The iLet Bionic Pancreas, an innovative insulin delivery device, continues to enhance diabetes management.
Read more →BBNXBeta Bionics, Inc. ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
Block & Leviton is investigating Beta Bionics, Inc. for potential securities law violations following a significant decline in share price. The company's shares dropped over 35% due to disappointing preliminary Q4 results, which included new patient starts that did not meet Wall Street expectations. Additionally, Beta Bionics disclosed receiving an FDA warning letter related to concerns found during an inspection of its facility. Investors who have lost money may be eligible to recover losses by contacting Block & Leviton.
Read more →BBNXBeta Bionics to Present at the TD Cowen 46th Annual Health Care Conference
Beta Bionics, Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026. The presentation will focus on the company's advanced diabetes management solutions, specifically their FDA-cleared iLet Bionic Pancreas. The event will conclude with a live audio webcast available on the company's website. This highlights Beta Bionics' role as a pioneering leader in insulin delivery technology.
Read more →BBNXBeta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026
Beta Bionics, Inc. reported its financial results for Q4 and full year 2025, showcasing strong performance and introducing guidance for 2026. The company highlighted its leadership in the durable insulin pump market and the successful completion of a Phase 2a trial for its bihormonal program. CEO Sean Saint expressed confidence in the company's growth trajectory and innovative pipeline.
Read more →BBNXBeta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Beta Bionics, Inc. has announced the release date for its fourth quarter and full year 2025 financial results, scheduled for February 17, 2026. The company will host a conference call and webcast to discuss its performance. The iLet Bionic Pancreas, an FDA-cleared device, exemplifies their commitment to improving diabetes management.
Read more →BBNX▼ -37%on this news
Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics
Beta Bionics, Inc. announced its preliminary, unaudited financial results for the fourth quarter of 2025, highlighting key metrics and inviting investors to in-person meetings to discuss the outcomes. The company plans to release complete financial results on February 17, 2026. The iLet Bionic Pancreas continues to be a significant innovation in diabetes management.
Read more →BBNXBeta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026
Beta Bionics, Inc. has announced that it will pre-release its topline financial results for the fourth quarter of 2025 during the week of January 5, 2026. The release is set to include key metrics such as net sales and new patient starts, emphasizing the company's growth trajectory. Additionally, management will hold in-person meetings in San Francisco from January 12-14, 2026, to discuss these results with investors. The company is notable for its innovative solutions, such as the FDA-cleared iLet Bionic Pancreas.
Read more →BBNXBeta Bionics Announces Participation at Upcoming Investor Conferences
Beta Bionics, Inc. has announced its participation in two upcoming investor conferences. The presentations will be available via live webcast and archived for future viewing. The company focuses on developing innovative diabetes management solutions, including the FDA-cleared iLet Bionic Pancreas, which autonomously manages insulin delivery.
Read more →BBNX▲ +10.3%on this newsshared move
Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance
Beta Bionics, Inc. reported its financial results for the third quarter of 2025, showcasing strong performance and raising its full year guidance. The company continues to lead in diabetes management solutions with the iLet Bionic Pancreas. A conference call is scheduled to discuss these results in detail.
Read more →BBNXBeta Bionics to Announce Third Quarter 2025 Financial Results on October 28, 2025
Beta Bionics, Inc. has announced the release of its third quarter 2025 financial results, scheduled for October 28, 2025. The company will host a conference call and webcast at 4:30 PM ET on the same day. Beta Bionics specializes in innovative diabetes management solutions, including the FDA-cleared iLet Bionic Pancreas.
Read more →BBNXBeta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance
Beta Bionics, Inc. reported its financial results for Q2 2025, showing a significant increase in net sales to $23.2 million, a 54% rise from the previous year. The company also raised its full-year revenue guidance from $82-$87 million to $88-$93 million, reflecting strong demand for its diabetes management solutions. However, Beta Bionics continues to face operational losses, with a net loss of $16.9 million during the quarter. The installed customer base saw remarkable growth, increasing by 200% to 24,085 users as the company ramps up its innovative product offerings.
Read more →BBNXBeta Bionics to Announce Second Quarter 2025 Financial Results on July 29, 2025
Beta Bionics, Inc. announced it will release its second quarter 2025 financial results after market close on July 29, 2025. Following the release, the company plans to host a conference call and webcast to discuss these results. The iLet Bionic Pancreas, their flagship product, aims to improve diabetes management through advanced technology. This announcement reflects the company's ongoing commitment to innovation and investor relations.
Read more →BBNX▼ -11.7%on this news
ADA Investor & Analyst Event June 2025
Beta Bionics, Inc. is scheduled to present at the ADA Investor & Analyst Event in June 2025, focusing on their iLet device and other product candidates. The presentation will cover the device's potential benefits, commercial updates, and clinical trial results. However, it warns investors of the substantial risks and uncertainties inherent in forward-looking statements. The company emphasizes the rapidly changing healthcare landscape and competitive market, which may affect their business outcomes.
Read more →BBNXBeta Bionics Announces Agreement with Abbott to Integrate the iLet Bionic Pancreas with Abbott’s Future Dual Glucose-Ketone Sensor
Beta Bionics has announced an agreement with Abbott to integrate its iLet Bionic Pancreas with Abbott's upcoming dual glucose-ketone sensor. This integration aims to enhance diabetes management by providing real-time decision-making support. The iLet is notable for being the first automated insulin delivery system that makes all insulin dosing decisions automatically, reinforcing the collaboration between the two companies in delivering advanced diabetes solutions. Beta Bionics emphasizes their commitment to improving outcomes for those requiring insulin therapy.
Read more →BBNXBeta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025
Beta Bionics, Inc. reported its financial results for the first quarter of 2025, showcasing a 36% increase in net sales and a remarkable 360% growth in the Pharmacy Benefit Plan channel. Despite these positives, the company experienced declines in gross margin and an increase in both operational and net losses compared to the same quarter in 2024. The installed customer base saw substantial growth, rising to 19,151 users. Additionally, Beta Bionics raised its annual revenue guidance for the year indicating a positive outlook for the business.
Read more →BBNXBeta Bionics to Announce First Quarter 2025 Financial Results on May 6, 2025
Beta Bionics, Inc. announced it will disclose its first quarter 2025 financial results on May 6, 2025, after market close. The company also plans to host a conference call and webcast on the same day. Beta Bionics is known for its innovative diabetes management solutions, including the FDA-cleared iLet Bionic Pancreas, which aims to enhance the treatment for people with diabetes.
Read more →BBNX▲ +21.6%on this news
Beta Bionics to Host Investor Event on June 22, 2025
Beta Bionics, Inc. announced it will host an investor event on June 22, 2025, coinciding with the American Diabetes Association's 85th Scientific Sessions in Chicago. The event will feature presentations from the management team, including updates on financial performance and a demonstration of the patch pump under development. Investors can attend in person or via a live webcast, with a replay available afterwards. The company continues to innovate in diabetes management solutions, notably with its FDA-cleared iLet Bionic Pancreas.
Read more →BBNXBeta Bionics Announces Board Appointment of Gerard Michel
Beta Bionics, Inc. has appointed Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Michel, who is currently the CEO of Delcath Systems, brings over 30 years of experience in the pharmaceutical and medical technology sectors. His expertise is expected to contribute significantly to Beta Bionics' efforts in scaling its commercial presence and enhancing its innovation pipeline for diabetes management solutions. This strategic move aligns with the company's mission to improve treatment outcomes for people with diabetes.
Read more →BBNXBeta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025
Beta Bionics reported substantial growth in net sales and patient starts for both the fourth quarter and full year of 2024, highlighting a remarkable increase in the Diabetes Management segment. The company also introduced forward-looking guidance for 2025, indicating estimated revenues between $80 million and $85 million. Despite the positive sales growth, Beta Bionics continues to face operational losses and a decrease in gross margin, which raises concerns about long-term profitability.
Read more →BBNXBeta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
Beta Bionics, Inc. will announce its fourth quarter and full year 2024 financial results on March 25, 2025. The announcement will be made after the markets close, followed by a conference call for performance review. The company continues to be a leader in developing innovative solutions for diabetes management, particularly with its iLet Bionic Pancreas device.
Read more →BBNXBeta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Irvine, CA.
Beta Bionics, Inc. has successfully closed its initial public offering, raising approximately $234.6 million. The offering included 13,800,000 shares, reflecting a strong interest as evidenced by the full exercise of an underwriters' option to purchase additional shares. The company is focused on developing advanced diabetes management solutions, with their iLet Bionic Pancreas standing out as a pioneering FDA-cleared device. The shares began trading on the Nasdaq Global Market under the ticker symbol BBNX.
Read more →BBNXBeta Bionics Announces Pricing of Upsized $204 Million Initial Public Offering
Beta Bionics, Inc. announced the pricing of its upsized initial public offering of 12 million shares at $17.00 each, raising $204 million. The shares are set to begin trading on the Nasdaq Global Market under the ticker BBNX on January 30, 2025. Additionally, a concurrent private placement is expected to yield an aggregate of $221 million. With its FDA-cleared iLet Bionic Pancreas, Beta Bionics aims to enhance diabetes management for insulin-requiring individuals.
Read more →BBNXBeta Bionics Files Registration Statement for Proposed Initial Public Offering
Beta Bionics, Inc. has filed a registration statement with the U.S. SEC for a proposed initial public offering of its common stock under the ticker symbol 'BBNX'. While the number of shares and pricing details are not yet disclosed, the company is collaborating with leading financial institutions as bookrunners for this offering. This move reflects Beta Bionics' ongoing efforts to expand its presence in the diabetes management market.
Read more →BBNXBeta Bionics Appoints Dr. Steven Russell as Chief Medical Officer in Preparation for the Commercial Launch of the iLet Bionic Pancreas System
Beta Bionics has appointed Dr. Steven Russell as the Chief Medical Officer to prepare for the commercial launch of the iLet Bionic Pancreas System. Dr. Russell, an experienced endocrinologist with a strong background in diabetes technology, will leverage his expertise to assist in obtaining FDA clearance. The iLet, a novel device designed to autonomously dose insulin, is aimed at improving diabetes management for users. This appointment reflects the company's commitment to advancing diabetes care through innovative technology and leadership.
Read more →BBNXBeta Bionics Appoints Sean Saint as CEO and Board Member
Caution: The iLet® Bionic Pancreas and iLet Duo™ are investigational devices limited by Federal (or United States) law to investigational use. Not available for sale. CONCORD, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. — a clinical-stage medical technology compa
Read more →BBNXBeta Bionics Appoints Gilad Glick to the Board of Directors and Veena Rao, Ph.D. as Chief Commercial Officer
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Gilad Glick, former Chief Executive Officer, Itamar Medical, appointed to Beta Bionics’ Board of Directors Veena Rao, Ph.D.,
Read more →BBNXBeta Bionics Announces Executive Leadership and Board Transitions in Preparation for Commercialization of the iLet Bionic Pancreas System
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Dr. Ed Damiano, President & CEO of Beta Bionics, is now assuming the role of Founder and Executive Chair Martha Goldberg Aro
Read more →BBNXBeta Bionics Announces Closing of $57 Million Series C Financing
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. The financing round was co-led by existing Series B and B-2 investors Soleus Capital, Perceptive Advisors, Farallon Capital M
Read more →BBNXBeta Bionics Announces Data Lock of the Insulin-Only Bionic Pancreas Pivotal Trial and Enrollment into the Screening Protocol of the Bihormonal Bionic Pancreas Pivotal Trial
The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. The iLet® Bionic Pancreas is a pocket-sized, wearable investigational medical device that is designed to autonomously determine and d
Read more →BBNXBeta Bionics Announces Appointment of Christy Jones to Board of Directors
IRVINE, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Christy Jones to its Board of Directors. “We are de
Read more →BBNXBeta Bionics Appoints Martha Aronson and Sean Carney to Its Board as Independent Directors
WEST CONCORD, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. — a medical technology company developing and aiming to commercialize the world’s first fully automated bionic pancreas system called the iLet® today announced that Martha G. Aronson and Sean D. Carney have
Read more →BBNXBeta Bionics Receives FDA Breakthrough Device Designation for the iLet™ Bionic Pancreas System
The iLet is a pocket-sized, wearable investigational medical device that autonomously controls blood sugar in people with diabetes and other conditions -- it is the world’s first bionic pancreas system FDA’s Breakthrough Device Designation Program provides Beta Bionics with prio
Read more →BBNXBeta Bionics and ConvaTec Announce Partnership to Bring Unomedical Infusion Set Portfolio to the iLet™ Bionic Pancreas System
ConvaTec is a leading global manufacturer of widely popular infusion sets offering a variety of patient choice Beta Bionics is developer of the iLet Bionic Pancreas System and is committed to device interoperability and patient choice ConvaTec will manufacture infusions sets fo
Read more →BBNXBeta Bionics Announces Closing of a $63 Million Series B2 Financing, Bringing the Total Series B and B2 Financings to $126 Million
The round was co-led by new investors Perceptive Advisors and Soleus Capital New investor Farallon Capital also participated in the round, as did previous Series B investors RTW Investments, ArrowMark Partners and funds managed by Eventide Asset Management Funds will support fi
Read more →BBNXBeta Bionics Announces Final Closing of Its $63 Million Series B Financing
New investors include ArrowMark, LifeSci Venture Partners, and strategic partner, Dexcom RTW made an additional Series B investment Strategic partner, Zealand Pharma completed $5 million Series B investment BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. – a medic
Read more →BBNXBeta Bionics Awarded Up to $2 Million NIH Small Business Innovation Research (SBIR) Grant
Award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Grant provides up to $2 million in funding over the next 24 months under the Fast-Track mechanism (pending demonstration of successful achievement of Phase I milestones) Research activities
Read more →BBNXBeta Bionics Secures an Initial $50 Million Series B Round
The round was led by Eventide Asset Management Other institutional investors in Series B include RTW Investments Corporate strategic partner and Series A investor, Novo Nordisk, has also participated in Series B Corporate strategic partner, Zealand Pharm, previously committed
Read more →BBNXBeta Bionics Announces Start of Home-Use Clinical Trials with the iLet™ Bionic Pancreas System and Receives IDE Approval from the FDA to Expand its Clinical Trials to Include the Senseonics Eversense CGM Integrated into the iLet
The Beta Bionics iLet Bionic Pancreas System is now approved for clinical trials in adults with type 1 diabetes (T1D) using two highly accurate continuous glucose monitoring (CGM) systems: the Dexcom CGM and the Senseonics Eversense CGM iLet compatibility with both CGM systems d
Read more →BBNXBeta Bionics Receives IDE Approval from the FDA to Begin a Home-Use Clinical Trial Testing the New iLet™ Bionic Pancreas System
First trial to test Fiasp® – Novo Nordisk’s latest formulation of fast-acting insulin aspart – using autonomous insulin delivery The bionic pancreas will also be tested with the conventional formulations of insulin aspart and insulin lispro in both adults and children with type
Read more →Competitive Position
How BBNX ranks across every disease it competes inCompetitive Position is a premium feature
See how BBNX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial